Department of Medicine-Division of Clinical Oncology, University Hospital of Patras, Rion-Patras, Greece.
Eur J Neurol. 2010 Jul;17(7):963-8. doi: 10.1111/j.1468-1331.2010.02966.x. Epub 2010 Feb 23.
To assess the significance of the ITGB3 polymorphism at residue 33 (ITGB3 L33P) in the development of chronic oxaliplatin-induced peripheral neuropathy (OXLIPN).
Fifty-five patients with advanced colorectal cancer were genotyped, using allele-specific primers and sybr green in real-time PCR. Patients had received adjuvant oxaliplatin-based chemotherapy. The severity of the OXLIPN was defined by means of the clinical total neuropathy score (TNSc). Following the discontinuation of treatment, 34/55 patients (61.8%) developed OXLIPN. Grade I neurotoxicity was revealed in 13 (38.2%) patients and grade II neurotoxicity in 21 (61.8%) patients.
Patients without OXLIPN (n = 21) were 19% homozygous for C, 33.3% were heterozygous, and 47.7% were homozygous for T. The corresponding percentages for patients developing any grade of OXLIPN (n = 34) were similar. About half of patients (46.1%) with grade I OXLIPN were heterozygotes (CT), 23.1% were CC, and 30.8% were TT. The majority of patients with grade II OXLIPN were TT (66.7%) with the remaining 33.3% being CT. The TT genotype was associated with increased severity of OXLIPN compared to the genotypes containing the C allele (P = 0.044).
The ITGB3 L33P seems to be unrelated to the development of OXLIPN, but it appears to be related to its severity.
评估 ITGB3 残基 33 位（ITGB3 L33P）多态性在慢性奥沙利铂诱导的周围神经病（OXLIPN）发展中的意义。
采用等位基因特异性引物和实时 PCR 中的 SYBR Green 对 55 例晚期结直肠癌患者进行基因分型。患者接受了辅助奥沙利铂为基础的化疗。OXLIPN 的严重程度通过临床总神经病变评分（TNSc）来定义。治疗停止后，55 例患者中有 34 例（61.8%）发生了 OXLIPN。13 例（38.2%）患者出现 1 级神经毒性，21 例（61.8%）患者出现 2 级神经毒性。
无 OXLIPN 患者（n=21）中，C 等位基因纯合子占 19%，杂合子占 33.3%，T 等位基因纯合子占 47.7%。发生任何程度 OXLIPN 的患者（n=34）的相应百分比相似。约一半（46.1%）的 1 级 OXLIPN 患者为杂合子（CT），23.1%为 CC，30.8%为 TT。大多数 2 级 OXLIPN 患者为 TT（66.7%），其余 33.3%为 CT。与携带 C 等位基因的基因型相比，TT 基因型与 OXLIPN 的严重程度增加相关（P=0.044）。
ITGB3 L33P 似乎与 OXLIPN 的发展无关，但与 OXLIPN 的严重程度有关。
